Clear All
731 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Tivozanib Fotivda 0.89mg, 1.34mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2021 In Use
NA Abemaciclib Verzenio 50 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Estradiol Estrace 0.5mg Hormonal Therapy Estrogen Yes 1998 In Use
NA Cyclosporine NeOral 25mg, 100mg Ancillary Therapy Immunomodulator Calcineurin Inhibitor Yes 1995 In Use
NA Dasatinib Sprycel 70 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Thalidomide Thalomid 150 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Abemaciclib Verzenio 150 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Abemaciclib Verzenio 100 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Aprepitant Emend 40 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
NA Avapritinib Ayvakit 100mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Cabozantinib Cabometyx 40 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Thalidomide Thalomid 50 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Belumosudil Rezurock 200mg Chemotherapy Rho Kinase Inhibitor ROCK1, ROCK2 Yes 2021 In Use
NA Axitinib Axitinib 5 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Encorafenib Braftovi 50mg, 75mg Chemotherapy BRAF Inhibitor V600E Yes 2018 In Use
NA Erdafitinib Balversa 3mg, 4mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Yes 2019 In Use
NA Crizotinib Xalkori 250 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
NA Lapatinib Tykerb 250 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2007 In Use
NA Lenalidomide Revlimid 5 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2005 In Use
NA Pomalidomide Pomalyst 1 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2013 In Use
NA Enasidenib mesylate Idhifa 50 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
NA Quizartinib Vanflyta Multiple Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2023 In Use
NA Letrozole Femara 2.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1997 In Use
NA Estramustine Phosphate Sodium Emcyt 140 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1981 In Use
NA Anagrelide Agrylin 1mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.